Pharmacopeia news from FierceBiotech
NewsPharmacopeia cuts 15% of workforce
In an effort to streamline its business and save cash, Pharmacopeia is laying off 15 percent of its workforce and decreasing "other expenses through improved operational efficiencies and increased Read more...
Pharmacopeia shares rise on blood pressure data
Pharmacopeia's shares were up today on trial results for PS433540, a hypertension drug. Data showed 'significant' blood pressure reductions in a Phase IIa study in patients with mild to moderate Read more...
AEterna's CEO, CBO resign
David Mazzo announced that he's resigning from AEterna Zentaris after exactly one year as CEO. Reasons for the move were not disclosed. Board chairman Juergen Ernst will serve as interim President Read more...
Solvay expands development pact with WyethSolvay and Wyeth Pharmceutical are expanding their existing neuroscience co-development and co-commercialization agreement to include research in neuroscience. The neuroscience co-development and co-commercialization partnership announced in April 2004 between Solvay and Wyeth resulted in an NDA for bifeprunox for the treatment of patients with schizophrenia. Meanwhile development continues on two other early-phase neuroscience projects, SLV313 and SLV314, which were part of that … Read more...Press Release: Pharmacopeia Enters Into a Research and License Agreement With WyethPress Release: Pharmacopeia Enters Into a Research and License Agreement With Wyeth Read more...Wyeth licenses Pharmacopeia's JAK3 programWyeth Pharmaceuticals has struck a development pact involving Pharmacopeia's JAK3 inhibitor program. The program focuses on the activation of T-cells for rheumatoid arthritis, psoriasis and other immunological conditions. Pharmacopeia retains commercialization rights for the treatment of dermatological and ocular diseases via topical administration while Wyeth gains all other rights in exchange for a $5 million upfront payment, up to $9 million in research funds over three years and up to … Read more...DEALS: AstraZeneca buys CAT for $1.3B
Pharmacopeia and Cephalon ink development dealPharmacopeia has launched a drug discovery partnership with Cephalon for an up-front fee of $15 million. Cephalon will identify compounds and both companies will work together to develop them. Whichever company chooses to develop a candidate will agree to pay the other a schedule of milestone payments. - read this AP report ALSO NOTED: Array BioPharma reaches milestone; Cytokinetics launches trial; and much more...> Array BioPharma has reached a milestone in its collaboration with Genentech. Release > Cytokinetics has launched a Phase I/II trial of SB-743921, a Kinesin Spindle Protein inhibitor. Release > Schering-Plough has selected a compound identified in its collaboration with Pharmacopeia for preclinical development in metabolic disease. … Read more...DEALS: GSK, Sirna sign $700M development deal
| Press ReleasesPharmacopeia CEO Resigns Pharmacopeia CEO Resigns 4/11/2008 PRINCETON, N.J., April 10 - Pharmacopeia, an innovator in the discovery and development of novel small molecule therapeutics, today announced that Leslie J. Read more... PRESS RELEASE: Pharmacopeia Earns Milestone Payment Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate PRINCETON, N.J., September 25, 2007 -- Pharmacopeia , an innovator Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends